

September 13, 2021

## Bal Pharma Limited: Ratings upgraded to [ICRA]BB+(Stable)/ [ICRA]A4+ from [ICRA]BB (Stable)/ [ICRA]A4

### Summary of rating action

| Instrument*                            | Previous Rated Amount (Rs. crore) | Current Rated Amount (Rs. crore) | Rating Action                                       |
|----------------------------------------|-----------------------------------|----------------------------------|-----------------------------------------------------|
| Long term – Fund-based facilities      | 50.00                             | 50.00                            | [ICRA]BB+ (Stable); Upgraded from [ICRA]BB (Stable) |
| Short term – Non-fund based facilities | 30.00                             | 30.00                            | [ICRA]A4+; Upgraded from [ICRA]A4                   |
| Long term – Term loan                  | 15.02                             | 15.02                            | [ICRA]BB+ (Stable); Upgraded from [ICRA]BB (Stable) |
| <b>Total</b>                           | <b>95.02</b>                      | <b>95.02</b>                     |                                                     |

\*Instrument details are provided in Annexure-1

### Rationale

ICRA has taken a consolidated view of Bal Pharma Limited (BPL / the company), which includes BPL and its subsidiaries (Lifezen Healthcare Private Limited, Balance Clinics LLP, Bal Research Foundation and Golden Drugs Private Limited), while assigning the credit ratings, given the common management and significant operational and financial linkages between them. Together, they are hereby referred to as BPL/the Group/the company.

The upgrade in the ratings factors in the healthy improvement in the operational and financial profile of the company during FY2021 and Q1FY2022, aided by healthy demand across both API and formulations segments and resumption of timely availability of raw material after the supply chain issues faced by the company in FY2020 and H1 FY2021. The company's operating margins improved to 9.8% in FY2021 (PY: 3.2%) and 10.6% in Q1FY2022 (PY: 9.7%) supported by relatively higher scale, improved product mix, backward integration and various cost control initiatives adopted by the company. The company has confirmed order book position of ~Rs. 55-60 crore which is to be executed in next three months and is expected to support the revenue growth of the company in FY2022. The ratings continue to draw comfort from the extensive experience of the promoters in the pharmaceutical industry and the well-diversified customer base of the company across domestic and export markets. The ratings also take into account BPL's manufacturing capabilities and its established position as a manufacturer of the anti-diabetic bulk drug, Gliclazide wherein it commands healthy market share in both domestic and export markets. The ratings also factor in the USFDA and EU GMP approved facilities which are expected to drive revenue growth, primarily in regulated markets.

The ratings remain constrained by BPL's average financial risk profile characterised by a leveraged capital structure and moderate debt protection indicators. Gearing stood at 2.1 times as on March 31, 2021 (2.7 times as on March 31, 2020). Interest coverage stood at 2.0 times, Total Debt/OBITDA at 4.6 times and DSCR of 1.4 times in FY2021 as compared to 0.4 times, 22.1 times and 0.3 times respectively in FY2020. With no major capex plans, scheduled repayment of the term loans and expected equity infusion (Rs. 4-4.2 crore in FY2022), the debt coverage indicators are expected to improve going forward. Further, the ratings factor in the high working capital intensity of operations due to the high inventory levels and elongated receivables cycles resulting in high utilization of its working capital borrowings. The ratings also remain constrained by the intense competition in the API and formulations business with limited pricing flexibility and the nascent stage of operations of the over-the-counter (OTC) business.

## Key rating drivers and their description

### Credit strengths

**Established position as a leading manufacturer of API for the anti-diabetic drug, Gliclazide; diversified customer base in the API and formulations segment** –BPL manufactures APIs, branded formulations, intravenous infusions and ayurvedic products. The company has a healthy market presence in domestic as well as export markets. Historically, formulations have been the largest business segment for BPL (55-60%); however, over the last few years, with strong ramp up in the API division, the company's business mix has witnessed a change. Under the API division, BPL manufactures the anti-diabetic drug, Gliclazide, and exports it mainly to regulated markets and holds 25% of market share globally. The company also manufactures bulk drugs covering other therapeutic areas such as neuropathic pain, anti-allergy, anti-inflammatory, acne treatment, etc. The company derives a majority (60-70%) of its total revenues from export markets, where it has presence in over 50 countries with no dependence on a single customer or region for its revenues. Under the API segment, BPL exports to regulated and semi-regulated markets such as Japan, Australia, Spain, UK, Canada, Iceland, Slovenia, Romania, Argentina, Brazil, Germany, South Africa, Serbia, Malaysia, Thailand, Turkey, Korea, Italy, Portugal, Poland, Netherlands, etc. Under formulation segment, BPL supplies its products to semi regulated and unregulated markets such as Africa, Latin America, Middle East, South East Asia and CIS countries.

**Improvement in revenues and profitability in FY2021 and Q1 FY2022 after a weak FY2020** – BPL has shown healthy improvement in its business and financial profile since Q1FY2021 aided by healthy demand across both API and formulations segments and resumption of timely availability of raw material after the supply chain issues faced by the company in FY2020. The company's operating margins improved to 9.8% in FY2021 (PY: 3.2%) and 10.6% in Q1FY2022 (PY: 9.7%) supported by relatively higher scale, improved product mix, backward integration and various cost control initiatives adopted by the company. The company has confirmed order book position of ~Rs. 59 crore which is to be executed in next three months and is expected to support the revenue growth of the company in FY2022.

**Expected equity infusion in FY2022** – BPL has issued 6,50,000 warrants to one of its promoter Mr. Shailesh D. S on a preferential basis at a price of Rs. 58 per warrant (nominal value of Rs. 10 and premium of Rs. 48). In March 2021, Rs. 4.18 crore has been received from the promoters. During FY2022, the promoters are expected to infuse further Rs. 4-4.2 crore, leading to improved liquidity and capitalisation indicators.

### Credit challenges

**High revenue dependence on Gliclazide which has high import dependence of raw material from China** – The company generates around 60-65% of its total API revenues and 45% of total revenues from Gliclazide. BPL imports 70-75% of its raw material for Gliclazide from China. Any disruption in the supply chain (as witnessed in FY2020) would impact the revenues and thereby profitability of the company. However, in FY2021, to reduce the exposure and dependence of import, the company has tied up with domestic suppliers for sourcing raw materials and is also exploring opportunities for backward integration. Further, in a bid to diversify its revenue stream and also provide fillip to the division's revenue growth, the company has increased focus on marketing the other products aggressively. Nevertheless, BPL's API revenues are likely to be skewed towards Gliclazide in the medium term given the time lag expected in ramp up of new products.

**Modest capitalisation and coverage indicators despite significant improvement in FY2021** – BPL has relatively high debt levels for its scale of operations on account of undertaking capacity addition across its manufacturing units. BPL's total debt of Rs. 113.2 crore as on March 31, 2021. Despite the significant improvement in the performance of the company aided by healthy demand across both API and formulations segments and resumption of timely availability of raw material after the supply chain issues faced by the company in FY2020 and H1 FY2021, the capitalization and coverage indicators continue to remain moderate. Gearing stood at 2.1 times as on March 31, 2021 (2.7 times as on March 31, 2020). Interest coverage stood at 2.0 times, Total Debt/OBITDA at 4.6 times and DSCR of 1.4 times in FY2021 as compared to 0.4 times, 22.1 times and 0.3 times

respectively in FY2020. However, with no major capex plans, scheduled repayment of the term loan and the planned equity infusion, the debt coverage indicators are expected to improve going forward.

**High working capital intensity** – The working capital intensity stood at 36% in FY2021 (PY: 51.2%). BPL's working capital intensity has traditionally remained high primarily owing to high inventory levels. Wide product portfolio in company basket results in high overall inventory levels. The company maintains inventory of three months on an average, depending on the products supplied, vendors validation, approval from authorities etc. On the debtors' front, high receivables period from Government institutions (under its institutional business) strains the working capital position of the company. However, the company has reduced its exposure to institutional buyers and has recovered most of its pending receivables from them. BPL is working on tighter control measures to contain the inventory and receivables period.

**Intense competition in domestic formulations business and API division** – The pharmaceutical industry is highly competitive due to the presence of various reputed companies resulting in limited pricing power and profitability.

## Liquidity position: Adequate

The company's liquidity position is adequate with improvement in fund flow from operations in FY2021 due to healthy revenue growth and improvement in OPM. BPL has also pruned its operating costs considerably thereby supporting its margin growth.

ICRA expects the company to maintain its liquidity position, supported by buffer from cash balances of Rs. 2.2 crore as on July 31, 2021 and adequate cash accruals. As on July 31, 2021, the company had Rs. 6.0 crore of unutilized working capital facility out of sanctioned limits of Rs. 68.0 crore. Debt repayment of Rs. 5.1 crore in FY2022, Rs. 5.9 crore in FY2023 and Rs. 5.5 crore in FY2024. The Group has no major capex plans for FY2022 and FY2023 and has also pruned its operating costs considerably. The company is expected to receive approximately Rs. 4-4.2 crore in FY2022, thereby supporting the liquidity position of the company. ICRA expects the Group to meet its near-and medium-term commitments through internal sources of cash and equity infusion through the issuance of warrants.

## Rating sensitivities

**Positive factors** – ICRA could revise the ratings if there is a substantial growth in the company's profitability, leading to an improvement in the liquidity position and the capitalisation and coverage indicators. A specific metric that could lead to an upgrade would be interest coverage of more than 2.8x on a sustained basis.

**Negative factors** – The ratings may be downgraded if the revenues decline or the cash accruals are lower than expected or if any major capital expenditure or BPL's inability to infuse funds through the issuance of warrants or improve its working capital cycle weakens the liquidity profile. A specific credit metric which could lead to a downgrade could be Total Debt/OPBDIT of 4.0x on a sustained basis.

## Analytical approach

| Analytical Approach             | Comments                                                                                       |
|---------------------------------|------------------------------------------------------------------------------------------------|
| Applicable Rating Methodologies | <a href="#">Corporate Credit Rating Methodology</a><br><a href="#">Pharmaceutical Industry</a> |
| Parent/Group Support            | Not Applicable                                                                                 |
| Consolidation/Standalone        | The ratings are based on the consolidated financials of the issuer                             |

## About the company

Bal Pharma Limited was incorporated as a private limited company in 1987 and is jointly promoted by Mr. Ghevarchand Surana of the Micro Labs Group, and the Siroya family. Micro Labs Limited holds an 8.84% (as on June 30, 2021) stake in BPL and is one of the leading players in the Indian pharmaceutical industry.

BPL manufactures active pharmaceutical ingredients (APIs), branded formulations, intravenous infusions and ayurvedic products. Its product offerings cover major therapeutic areas like diabetology, cardiology, mother and childcare, orthopaedics, neurology and post and pre-operative surgical medication. The company also carries out the contract manufacturing of bulk drugs and undertakes bulk manufacturing for supplying to government institutions. In the exports segment, BPL mainly caters to unregulated and semi-regulated markets in the formulations segment and regulated markets in the bulk drugs segment.

### Key financial indicators (audited)

| BPL Consolidated                                     | FY2020 | FY2021 |
|------------------------------------------------------|--------|--------|
| Operating Income (Rs. crore)                         | 171.6  | 250.6  |
| PAT (Rs. crore)                                      | -12.9  | 4.7    |
| OPBDIT/OI (%)                                        | 3.2%   | 9.8%   |
| PAT/OI (%)                                           | -7.5%  | 1.9%   |
| Total Outside Liabilities/Tangible Net Worth (times) | 4.3    | 3.5    |
| Total Debt/OPBDIT (times)                            | 22.1   | 4.6    |
| Interest Coverage (times)                            | 0.4    | 2.0    |

Source: Company and ICRA research; PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation

### Status of non-cooperation with previous CRA: Not applicable

### Any other information: None

### Rating history for past three years

|   | Instrument                | Current Rating (FY2022) |                          |                                                   |                         | Chronology of Rating History for the past 3 years |                     |                         |                         |                         |
|---|---------------------------|-------------------------|--------------------------|---------------------------------------------------|-------------------------|---------------------------------------------------|---------------------|-------------------------|-------------------------|-------------------------|
|   |                           | Type                    | Amount Rated (Rs. crore) | Amount Outstanding as of Jul 31, 2021 (Rs. crore) | Date & Rating in FY2021 | Date & Rating in FY2021                           |                     | Date & Rating in FY2020 | Date & Rating in FY2019 | Date & Rating in FY2018 |
|   |                           |                         |                          |                                                   |                         | Sep 13, 2021                                      | Mar 15, 2021        |                         |                         |                         |
| 1 | Fund-based facilities     | Long term               | 50.00                    | 61.0                                              | [ICRA]BB+ (Stable)      | [ICRA]BB (Stable)                                 | [ICRA]BB (Negative) | [ICRA]BB (Negative)     | [ICRA]BBB (Stable)      | [ICRA]BBB (Stable)      |
| 2 | Non-fund based facilities | Short term              | 30.00                    | 21.4                                              | [ICRA]A4+               | [ICRA]A4                                          | [ICRA]A4            | [ICRA]A4                | [ICRA]A3+               | [ICRA]A3+               |
| 3 | Term loan                 | Long term               | 15.02                    | 36.9                                              | [ICRA]BB+ (Stable)      | [ICRA]BB (Stable)                                 | [ICRA]BB (Negative) | [ICRA]BB (Negative)     | [ICRA]BBB (Stable)      | [ICRA]BBB (Stable)      |

Source: BPL and ICRA research

### Complexity level of the rated instruments

| Instrument                | Complexity Indicator |
|---------------------------|----------------------|
| Fund-based facilities     | Simple               |
| Non-fund based facilities | Very Simple          |
| Term loan                 | Simple               |

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analyzing an entity's financial, business, industry risks or

complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments, is available on ICRA's website: [www.icra.in](http://www.icra.in) .

#### Annexure-1: Instrument details

| ISIN No/Banker Name | Instrument Name           | Date of Issuance | Coupon Rate | Maturity | Amount Rated (RS Crore) | Current Rating and Outlook |
|---------------------|---------------------------|------------------|-------------|----------|-------------------------|----------------------------|
| NA                  | Fund-based facilities     | NA               | NA          | NA       | 50.00                   | [ICRA]BB+ (Stable)         |
| NA                  | Non-fund-based facilities | NA               | NA          | NA       | 30.00                   | [ICRA]A4+                  |
| NA                  | Term loan                 | Mar 2020         | 10.75%      | FY2026   | 15.02                   | [ICRA]BB+ (Stable)         |

Source: Company

#### Annexure-2: List of entities considered for consolidated analysis

| Company Name                       | BPL ownership | Consolidation Approach |
|------------------------------------|---------------|------------------------|
| Golden Drugs Private Limited       | 100.00%       | Full Consolidation     |
| Balance Clinic LLP                 | 80.00%        | Full Consolidation     |
| Lifezen Healthcare Private Limited | 51.00%        | Full Consolidation     |
| Bal Research Foundation            | 80.00%        | Full Consolidation     |

Source: Company

## ANALYST CONTACTS

**Shamsher Dewan**

+91 124 4545328

[shamsherd@icraindia.com](mailto:shamsherd@icraindia.com)

**Kinjal Shah**

+91 22 6114 3442

[kinjal.shah@icraindia.com](mailto:kinjal.shah@icraindia.com)

**Faizan Ahmed**

+91 80 4332 6414

[faizan.ahmed@icraindia.com](mailto:faizan.ahmed@icraindia.com)

**Mythri Macherala**

+91 80 4332 6407

[mythri.macherala@icraindia.com](mailto:mythri.macherala@icraindia.com)

## RELATIONSHIP CONTACT

**Jayanta Chatterjee**

+91 80 4332 6401

[jayantac@icraindia.com](mailto:jayantac@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**

Tel: +91 124 4545 860

[communications@icraindia.com](mailto:communications@icraindia.com)

## Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited



### Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001  
Tel: +91 11 23357940-45



### Branches



© Copyright, 2021 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.